Allen Chankowsky: Against All Odds – From a Terminal Diagnosis to His Approach that Saved His Life

In this documentary, ultra-rare cancer survivor Allen Chankowsky shares his incredible journey of resilience, hope, and self-advocacy after being diagnosed with Hodgkin’s lymphoma at 20 and later with stage 4 salivary duct carcinoma.

Faced with this rare and aggressive cancer, Allen and his partner, Cynthia, conducted their own research and turned to comprehensive genomic profiling, uncovering a genetic mutation linked to prostate cancer. This discovery led them to pursue hormone therapy, which proved successful, despite the initial treatment plan suggesting palliative chemotherapy—a “kiss of death,” as Allen later describes.

Allen’s story highlights the power of precision medicine, self-advocacy, and the critical role of mental health support in cancer care.

Allen Chankowsky: Hi, I’m Allen Chankowsky. I am 55 years old this month, and I was born in Montreal, Quebec, Canada, and now live in Toronto, Ontario, Canada. I have two children.

I have two living parents. I have a beautiful girlfriend, and she has two beautiful kids. I had two types of cancer, and the first time I had cancer was in 1991, when I was 20 years old, and I was diagnosed with a cancer called Hodgkin’s lymphoma, and that diagnosis occurred three years after one of my siblings died in a car accident.

So I was very nervous for my family, for my parents, who may be dealing with another child that they would have to say goodbye to. So I was very concerned when I was first diagnosed with Hodgkin’s disease, of its impact on my family, and of course that impacted me. So I was very nervous, and I was very secretive about that diagnosis.

I didn’t share it with my parents immediately. I wanted to first make sure that I actually had cancer and that I had a treatment plan in front of me before I kind of let them into that world with me. But I did eventually let them into my world, and that was a very difficult period for me and for my family, for my friends, and for my extended family.

It was very, very difficult. So in 1991, I was only treated with radiotherapy, and that radiotherapy was targeted to my mantle area, upper mantle area, and my head and neck area, and then that was it. And then I was, every three months, doing blood tests and scans, and then three months went to six-month intervals, and then the six-month intervals went to one-year intervals after like three years.

And then I became five years clear of my Hodgkin’s disease, and everyone’s saying, wow, you reached the five-year mark, and it’s an amazing milestone to reach. And I agreed. It felt good reaching that milestone.
But I always knew in my head that I don’t want to get too ahead of myself and thinking that I beat cancer, because I think once you have cancer, it’s kind of always inside of you. Maybe it’s dormant, maybe it’s alive to a little extent, but I never really wanted to say, hey, you know, I succeeded over cancer. I resisted ever doing that.

Every year I went to the Princess Margaret Cancer Center to get followed up for my Hodgkin’s disease, and everything was fine. Everything was fine. My blood tests were fine.

My physical exams were fine. Nothing revealed anything suspicious. However, it was me that found a lump on my right side of my neck in July of 2016, and I felt like after so many years of being followed up for my Hodgkin’s disease, so many years of being palpated here and everywhere, and when I felt that lump, I felt like it was something that needed to be addressed medically.

So I went to the emergency department of the Princess Margaret, and they did a biopsy, and they knew it was cancer, except they didn’t know what type of cancer it was. So that’s when they told me that I would need a neck dissection, which is a horrible name for an operation, and a head and neck cancer oncologist, surgical oncologist, performed the operation, and it was a very long surgery.

They removed, I believe it was 68 lymph nodes from my neck, and about 40% of those lymph nodes were positive for cancer, and it was determined in 2016 that this cancer was called salivary duct carcinoma, which is a subtype of a salivary gland cancer.
It’s the most aggressive salivary gland cancer, which is itself a very rare disease, and it was diagnosed at stage four. So there I was again on the radiation table. It’s now 2016.

The radiation therapy I had in 2016 for my salivary duct carcinoma occurred every day for one month, twice a day, once in the morning and once at night. That’s in a very, very aggressive treatment approach for radiation therapy. So it was difficult.
It was a difficult therapy, but I did it, and after the therapy, I had my CT scans three months after that, and it was determined that the cancer had indeed spread to my lungs. So the radiation therapy that they tried to do with curative intent did not result in a curative attempt. It had already migrated to my lung, and I was in a very precarious situation.

It was time for me to prepare myself for the inevitable when you have terminal cancer, and as a young man with two young kids, two living parents who already buried a kid, I was in a position where I needed to either accept my fate and accept the palliative chemotherapy that was offered to me or try something different. After the radiation therapy, three months after that, I had my CT scans in late 2016, and it showed that the cancer had spread to my lungs, and Cynthia and I realized then that we needed to research this.

We needed to find whatever we could that could help us figure this out because I knew with Dr. Su being my oncologist at the time, I already knew what the standard of care was going to be, and the standard of care for salivary duct carcinoma is palliative chemotherapy.

Lillian Siu: In Allen’s case, he had standard of care at that time, which in the late 2016 era, it was really chemotherapy still, but some early glimpses of targeted therapy if we’re able to identify targets and able to find drugs suitable. But these options are both discussed and offered to him if it’s appropriate.

Allen Chankowsky: Accepting the palliative chemotherapy is like accepting the kiss of death. It’s basically you’re saying, okay, cancer, I have nothing. I have no fight in me.
Just give me as long as I can have with the palliative chemotherapy, and let’s call it a day. I wasn’t ready to call it a day yet.

Lillian Siu: He is a very resourceful individual, and I also understand his philosophy of life. He’s a fighter. He’s a survivor.
He wouldn’t just take everybody’s work for granted. He wanted to find out more about his own cancer, and he did a lot of research on his own. He came up with a lot of ideas, some of which probably is not too scientific, but some of them are very legitimate and scientific.
We had a very good discussion about what is probably not in the mainstream and what is very much still investigational but scientifically based.

Allen Chankowsky: When Cynthia and I did the research, and we realized that we needed to send out the tumor for comprehensive genomic profiling, that was going to be the only possible hope that we had in trying to unlock the keys of this cancer. We needed to find what was wrong with the cancer. We needed to find the cancer’s vulnerability.
We needed to find its weakness. And the only way to do that in 2016 was to send it out for comprehensive genomic profiling.

Lillian Siu: Patients are devoted to their disease. They can uncover things that even physicians that are extremely knowledgeable may not know about the disease.

Allen Chankowsky: So in Canada, there is no company that receives tumor to do comprehensive genomic profiling. It just doesn’t exist here yet. So what we did was we explored other companies in the United States, and I arranged for the tumor to be sent out from Princess Margaret Hospital to Cambridge.
And they did the comprehensive genomic profiling there. And we realized when the report came back that my cancer has a mutation, a driver in it that is shared with prostate cancer, and that driver is called androgen receptor positive driver.

Lillian Siu: Even then, the type of tumor he has, there are some oncogenic drivers. It has expression of hormone receptors that very much are similar to breast cancer and to prostate cancer. It’s one of these tumors that have that kind of genotype.
They can have receptors to HER2 and they have receptors to androgen receptor.

Allen Chankowsky: Because the tumor was androgen receptor positive, we knew from the prostate cancer world that hormone therapy offers many prostate cancer patients with this driver many, many years of life. And we saw through some of the research that we did that some of the people with salivary duct carcinoma who also have an androgen receptor positive driver were benefiting from hormone treatment.

So we printed off all the peer-reviewed journals and we had an appointment with Dr. Su. And we walked into that meeting with Dr. Su. And in her hand, she had the paperwork that she wanted me to sign that was going to be for the palliative chemotherapy. And I was scared, petrified.

I have stage 4 cancer. There was no good treatments ahead of me. And here I am in front of Dr. Su, a world-renowned leader in head and neck cancer and immunotherapy, looking at her in her eye and saying to her, I’m not doing it. I want to do this instead. And I showed her the paperwork and we sat down together, her and I and Cynthia, and we looked at it together. And Dr. Su said, you know what?

If you want to try this, let’s do it. You have nothing to lose. And she was right.
I had nothing to lose.

Lillian Siu: I don’t take the credit. I mean, Allen, to his own credit, did a lot of the research and drove a lot of his own diagnosis and therapeutic decisions. And I think we as physicians just support him where we can.

Allen Chankowsky: She accepted trying it. She prescribed it for me. I tried it.
And three months later, we sat down together again and we reviewed the results of my CT scans. And she said, you know what? This is working.

I’m going to transition your care now to the GU clinic. So I went from the head and neck clinic to the GU clinic. And there I was as a, you know, 47-year-old man, sitting in the prostate cancer clinic with, you know, the 60-, 70-, 80-year-old gentleman with a head and neck cancer in the prostate cancer clinic.

And it was remarkable. Remarkable. My story and the drive that I have to tell my story involves comprehensive genomic profiling and understanding that cancer is a disease of the genes, that you can’t have cancer without having a genetic or genomic aspect to it.
And in difficult-to-treat cancers, or in my opinion, in every cancer needs to be comprehensive genomically profiled. There needs to be full genome sequencing involved. And if patients aren’t doing that work, they need to ask for it, because it’s the only way of knowing what cancer you actually have.

Lillian Siu: Let me define precision medicine for you. It comes from the word precise. And the idea is to understand what is wrong with the tumor and why the tumor is a tumor, and to understand it at a very basic level, at the genomic, at the DNA level, because it’s the DNA abnormalities that drive the tumor.
And then when we have a precise understanding of what is wrong with the tumor, then we can treat it by targeting those abnormalities.

Allen Chankowsky: Without knowing that information, all you know is that you have a particular cancer located in a particular part of your body. But that’s not the important part. The important part is what’s driving this cancer.
And you can only know that information if your doctor orders the appropriate genomic and genetic testing that would identify exactly what’s wrong with the cancer and what targeted therapies could be used against it. Without knowing that information, a patient and their doctor are blind to the appropriate treatment.

Lillian Siu: Before we had genomic sequencing available, all tumors were treated based on where they originated. So if you had a colon cancer, it was treated, it originated from the colon, and you were treated as if you have a colon cancer. If you had a tumor that originated in the lung, it was treated as a lung cancer, and so forth.

But one has to understand, and this still is not a completely accepted view, that saying that a cancer originated from the colon doesn’t tell you what is going on in that cancer that made it a cancer. And you could take 100 patients with colon cancer and each of their tumors are different. And this may be the reason that our standard or old treatments were not very successful because we were kind of guessing as to what the treatment was.

Allen’s a very interesting individual. He is extremely intelligent, very high-functioning, and he is very proactive in his own diagnosis and care. And I think I’ve learned that in such a situation, the physician can consider that actually a very fruitful relationship.
You can actually work together with your patients. And sometimes it may feel, for some physicians, feel threatened by the fact that the patients are bringing up choices or options that they have not thought of. I think it’s a good lesson that it doesn’t always have to be that way.

The patients being their own champion is sometimes very helpful. And in his case, he’s not just being his own champion. He’s actually being a champion of patients with similar diseases as his and rare tumors in general.

So I think it’s a great model, a role model, for many, many individuals, physicians and patients, to understand we can often channel that kind of energy into very positive strengths to make the whole field as patient advocacy, as survivors, and really make sure that we erase or eradicate any sort of disparity and access issues. So I think I consider this a very positive experience. And, you know, thank goodness for individuals like Allen who have that spirit to fight for himself and fight for others.

Allen Chankowsky: Once I did my research together with Cynthia in terms of what would be my best treatment to outlive the statistics that were just abysmal for this disease, once we realized that the research that we did was successful, that was probably the most uplifting moment.

When I got my results from the CT scans three months after trying a targeted treatment, a treatment that Cynthia and I researched, a treatment that my oncologists did not suggest that we do, a hormone-based treatment, that my head and neck cancer was being treated as a prostate cancer because of a genetic driver being shared with prostate cancer, realizing that being treated as a prostate cancer patient for a head and neck cancer was the key to outliving my statistics for salivary duct carcinoma.

That, to me, after receiving those results of the CT three months after trying that treatment, saying that the tumors were shrinking and that the treatment was working, that, to me, was the most uplifting moment for sure because I realized in that moment that the work that I did as my own advocate, the work that Cynthia helped me do as her being my advocate in terms of the research that we did, it worked.

It worked. And that’s what I want other patients to know, that just because you have a bad cancer or a terminal cancer, that it doesn’t mean it’s the end right away. It means that there’s opportunity to explore targeted treatments, that there are other options available.

You just have to know what to ask for. You just have to know what to do.

Lillian Siu: It was really insightful of Allen to do the research and actually to figure out a way to treat his cancer.

Allen Chankowsky: There’s a foundation out of Boston called Target Cancer Foundation, and it’s all they do is they focus on the rare cancer community because patients of rare cancers, we are in a very difficult position because unlike the common cancers like breast and prostate and colon, people with rare cancers don’t benefit from the research that is done like in breast cancer, prostate cancer, colon cancer, the common cancers.

And the reason why research isn’t done for rare cancers is because pharmaceutical companies, they don’t have the incentive to put money behind cancer or a type of cancer that is so rare that the incidence of people needing a therapeutic, it doesn’t pay them to research and develop a therapeutic.
So Target Cancer Foundation is really the only foundation in the United States, dare I say the world, who focuses on the rare cancer community and they are doing incredible work in the space. And I’ve met a number of very prominent researchers and scientists who are in the rare cancer space who are doing incredible work. And I’m happy to say that rare cancer patients today, they do have options.

There are options available where 10 years ago, those options weren’t available. So if anyone watching does have a rare cancer, there are options. Things are not bleak for rare cancer sufferers anymore.

Jim Palma: Well, I think Allen’s story, unfortunately, perfectly represents what is a very common experience in rare cancers, that a person would be diagnosed with a rare cancer for which there’s not a lot of knowledge, for which there are very few treatments or clinical trials, and also might be treated by a physician who hasn’t treated a lot of that type of cancer in their career. So all of those things lead to so many challenges for patients and I think Allen’s experience really reflects that. The other part of Allen’s experience that I think is very important in rare cancers is that he’s really taken it upon himself to become an expert in this type of cancer.
And this is something that we see very often with patients with rare cancers, is that they take on this role themselves of becoming scientific experts, experts on the landscape of treatments and clinical trials, and also experts in their own data, in ways that they can even begin to interpret that data or work with it and present it to their doctors themselves in the hope of making sure that they’re finding the right treatment. I’ve always been so impressed by the way that Allen has done that and the impact that it’s had on his treatment over the years.

Razelle Kurzrock: Now with genomic sequencing, the science is evolving very quickly. It’s not perfect, but we can understand exactly what is driving the tumour. And then we increasingly have drugs that can precisely, and that’s that word again, precise, that goes to precision, precision medicine, target those abnormalities.

And while it’s not perfect yet, we see much, much better responses. As you might expect, when we’re not guessing, but instead we’re actually targeting the abnormalities that make that tumour a tumour. Now I don’t want to hype this up and give people false hope because the science isn’t perfect, and that doesn’t mean that we can do this for all patients, but some of the things that are amazing are, I have patients that I treated back in 2015, 2016, that had end-stage disease, and we figured out exactly what was wrong with their tumour.

And in a couple of these patients, as an example, they had high tumour mutational burden, which we now know predicts response to immunotherapy. Those patients have gone into complete remission or are still in complete remission years later. This was unimaginable 15 or 20 years ago.

So definitely doesn’t happen for everybody yet, but we definitely see patients where we can far exceed the expectations if we give them the right treatment for their tumour.

Allen Chankowsky: If anyone was to get cancer today, I got to tell you that there are so many treatments available, there’s so many modalities that are available, but you have to know what type of cancer you have. You have to do comprehensive genomic profiling to get targeted therapy.

Jim Palma: Every patient with every cancer, but certainly every patient with any rare cancer should have genomic profiling as soon as possible after their diagnosis. You know, what we’ve seen over the past few years is so much progress in the development of molecularly targeted therapies, and in many cases, these therapies are even approved by the FDA not for a single indication, but for any type of solid tumour that has this particular mutation.

So for a patient with a rare cancer that has no established treatment, by getting biomarker testing done and hopefully identifying actual mutations, now they may be eligible for these treatments, not necessarily designed for their disease, but designed for the mutation.

That opens up a lot of opportunities for patients, and it really allows patients with rare cancers where it’s unlikely a company would develop a drug for such a small rare cancer to benefit from a drug that already has been developed and FDA approved.

So in our TRACK clinical trial, one of the key elements of that trial is that as soon as patients enroll, we help them to get biomarker testing of tissue and blood at no cost, and we use the results of that biomarker testing to power a meeting of our molecular tumour board, who then makes recommendations for treatments based on those reports. So in our mind, and certainly as part of our mission, helping patients access biomarker testing is absolutely critical, and it’s something we’ve tried very hard to do, and really we built the TRACK clinical trial around that idea.

Allen Chankowsky: The most difficult part in 1991 was my fear of dying early and that impact on my family, on my parents. That was really my most problematic area for me, the most concern that I had. I saw them bury my brother.
I saw the effects. I’ve seen that movie before. To know that I would be responsible for playing out act number two in that movie, very, very difficult on me.

Very difficult. So my motivation was to live so that they wouldn’t have to suffer that again.

Madeline Li: When he first started working with me, his focus was very much on protecting his family and keeping the details around his cancer hidden from his family because he wanted to protect them. He did that really well so that people really weren’t aware of what was happening and he was holding everything on his own, which increased the level of distress, both in himself and in his partner. And then when he, working in therapy, he came to an understanding that maybe it wouldn’t be that harmful, like it was less harmful to be transparent with his family about what he was going through and even with himself.

Allen Chankowsky: In 2016, it was very, very different. I knew that after my surgery, that I had stage four, that this was in fact a terminal diagnosis. So I was demoralized.
I was absolutely demoralized. And what amplified that feeling even more was now that I had two young kids. But it was because of those two young kids, they were really my motivation to keep going, to show them that you don’t give up, that even when you’re told that you have terminal cancer, even when things look so, so bad, that you don’t give up.

I had a responsibility to show my kids that you don’t give up in the face of adversity. You don’t give up. You try the best that you can until you can’t no more.
So they kept me going. My girlfriend kept me going. And my parents certainly kept me going.

But I did feel very strongly that my days were numbered. I did feel very strongly that I was going to die a young man. And that’s hard.

It’s a hard pill to swallow. And because of that, because of that effect, I wasn’t able to talk about it with really anybody other than Cynthia and my psychiatrist who works at the Princess Margaret Cancer Centre. That was a big part of my treatment.

Madeline Li: He adopted an attitude of he’s going to beat the odds. That’s how he is coping with this. And this is something he learned from backgammon.
It was a beautiful analogy he wrote to me once about that. He understands the situation, obviously. He’s being very transparent about it now.

But he is dealing with it by being proactive, by advocating for himself and directing care. And the quote that he learned from backgammon and wrote to me, which I think really epitomizes him, is I don’t expect to win so long as I keep playing.

Allen Chankowsky: People often think that cancer treatment is the physical treatment of surgery, chemotherapy, radiation, targeted therapy, precision medicine. That’s all very, very important. That’s what saves lives, for sure.
But at the end of the day, cancer treatment also involves the mental health aspect. And that treatment, that mental health care that I received from the Princess Margaret Hospital, I feel actually saved my life.

Madeline Li: Often, and I think partly in Alex’s case, depression is a side effect of cancer treatment and various immunotherapies, the stress on your body. And it’s a physiological reaction like pain or fatigue. And it needs to be treated if it’s there.
Because actually, there’s pretty clear evidence that depression is an independent risk factor for reduced survival in cancer. So if two people have the same disease at the same disease stage, one has depression, their chances of survival are lower. So it’s important to treat.

And there are many kinds of effective treatments. I often say the need for mental health support in cancer isn’t because you’re crazy. It’s because you’re living with a crazy situation.
And everyone with cancer could use some support.

Allen Chankowsky: It was through that psychological work that allowed me access to skills that I never knew I had access to. It allowed me to write my book. And it allowed me to realize that I need to be more open about this.
That it wasn’t healthy to be closed. And the mental health impact was a big part of my treatment.

Madeline Li: Everything he does, he does to extremes and with excellence.

Allen Chankowsky: When it became clear that I was going to outlive the statistics on my cancer and that the work that Cynthia and I did was successful, I realized then that I cannot keep this information to myself. I realized then that other patients and their families need to understand what I did together with Cynthia that translated into me outliving the statistics of my cancer.

Madeline Li: There’s this concept that we talk about which is called post-traumatic growth or benefit finding. Post-traumatic growth is the opposite of post-traumatic stress. When you’re facing something like a terminal diagnosis, some people come out of that better.
And post-traumatic growth means learning to reprioritize what’s important to you in life.

Allen Chankowsky: So I wanted to share. I wanted to expose other people to what I did so that it can help them in their own cancer journey.

Jim Palma: He’s gained expertise in two ways. One, as an advocate for his own care and as a scientific expert in his disease and how to best treat it. But also as an advocate publicly for rare cancers and using a really powerful and eloquent voice to tell his story and help people understand why they have to pay attention to rare cancers and why they have to think about precision medicine.
And I’m just very, very grateful for that.

Lillian Siu: He is actually advocating for patients with rare cancers and really promoting support from the academic community to provide patient voice to those with rare cancers to make sure we don’t forget these cancers that are not so common and sometimes are forgotten in clinical trials or even forgotten in routine practice to accumulate that information to learn from experiences. So it is very gratifying that a patient is actually paying it forward this way.

Allen Chankowsky: The other motivation to write the book was to leave a legacy, particularly for my children. For them to hold near and dear to their hearts that when I am no longer here, that when they get to their various stages of their own life, that they can pick up the book whenever they want and they can read parts of it. They could understand the difficulty that I had and trying to overcome those difficulties and how I tried to help other people and how I wanted to show them that you never give up.
And I felt that my book would be that thing of permanence that would always be available to them.

Madeline Li: Once he decided that he was going to be transparent about his cancer diagnosis, he did that to extremes and with excellence and actually wrote a book. And now it’s not just telling his family, he told the whole world. And that is Allen.

Allen Chankowsky: I hear from other patients on an ongoing basis that it is helping them, that my story has helped them and that they’re sharing the book with other people. And that is the best news that I could receive when I receive an email from a complete stranger from some corner of the world who has reached out to me to say thank you. I mean, that just makes my day whenever I receive a message like that.

Thankfully, the treatment that I’ve been on since 2017 is basically, it’s a hormone-based treatment. It’s an injection that I receive once every three months and it’s pills that I take every day. And the treatment is designed to control the cancer by starving it of the hormone androgen that it needs to live.

Razelle Kurzrock: I think Allen is extraordinary. And the reason he’s extraordinary is because he’s lived many, many years beyond what people would normally live with his type of tumor that is metastatic. And he’s done that by thinking about the science and by advocating for himself.

Allen Chankowsky: I’m able to live my life. Is it perfect? No. Are there side effects from the treatment? Yes. Not pleasant.
Not pleasant. But certainly not as bad as the intense side effects of chemotherapy. This is a form of chemotherapy, but it is not as intensive as side effects as chemotherapy is.

But it is an everyday treatment. Pills every day. Injections once every three months.
And it’s keeping me alive. It’s allowing me to watch my children grow into young adults. My son’s 20 now.

My daughter’s 17. So I’m getting gray hair.
I put a little bit of weight on. I’m getting old. I mean, I’m living the life.
I’m living the life. I’m getting old. I mean, that’s the goal for me, right?
I want to get old. I want to get gray. No matter how bad you think your cancer is, there is hope.
There is hope. And I’m not just saying that because, you know, I hear of other people who have had positive experiences, which that is the case. I have heard.

But I’m talking about from personal experience that even having a terminal diagnosis of cancer, that there is hope. All you have to do is know what the correct things to ask for, what the testing to do, to ask for genomic profiling, for RNA sequencing, and to help identify exactly what type of cancer you have. And once you know that information, then you can find a targeted therapy, even with a terminal diagnosis.

There is hope. So please don’t be discouraged by a cancer diagnosis. That’s the first thing, you know, that I learned.
The other thing is that as difficult as it might be, try to be open about talking about your cancer experience. I found that for me, the more open I became, the easier it was for me to walk around, you know, with the burden of having cancer. I found it easier to reintegrate into society, so to speak, being more open about it.

And the third lesson I learned, I recently had a birthday, beginning of July. And this birthday was similar to the other birthdays I’ve had since 2016, where you don’t know if this is going to be your last birthday. And every birthday that I have, you know, I say to myself, am I going to see the next one?

And for me, I live life in a different way, knowing that this could be my last birthday. So the moral of the story here is that live life as though you’re not going to see your next birthday. Live life in that way.
Look at the people who you love and ask yourself, am I going to be celebrating my birthday next year with these people, or am I going to be dead? And that allows me to live life in a more full way, more appreciative way. And it makes me feel good.

Madeline Li: And I often say to patients, you can’t be so focused on dying that you forget to live now. And so in the time remaining, what has meaning for you? For Allen, it’s always been clear.
What brings him meaning is his family. And so he will always do what’s in the best interests of his children, his partner and his parents. He will always, even before what’s in his own best interests, his actions will be guided by what’s in his family’s best interest.
That’s what brings him meaning.

Allen Chankowsky: So my life has changed in that direction. And I got to tell you, it’s surprising even to me, but I’m here talking about it, so I’m happy.

For more information visit oncodaily.com